export interface ArticleReference {
  title: string
  source: string
  year: string
  doiOrUrl?: string
  type: "Journal" | "Regulatory Gazette" | "Clinical Trial" | "Industry Report"
}

export interface Article {
  slug: string
  title: string
  dek: string
  category: "Pharma" | "MedTech" | "AI-Health"
  format: "Feature" | "Analysis" | "Interview" | "Digest"
  issueId: string
  authorId: string
  date: string
  readingTime: string
  tags: string[]
  image: string
  body: string[]
  isLocked?: boolean
  references?: ArticleReference[]
}

export const ARTICLES: Article[] = [
  {
    slug: "continuous-biomanufacturing-cdmo-scaleup-2026",
    title: "Continuous Biomanufacturing at Scale: How Indian CDMOs Are Accelerating APAC Biologics",
    dek: "A deep dive into perfusion bioreactor economics, single-use technology adoption, and regulatory validation for commercial biologic APIs.",
    category: "Pharma",
    format: "Feature",
    issueId: "issue-2026-09",
    authorId: "auth-arun-sharma",
    date: "Sep 02, 2026",
    readingTime: "8 min read",
    tags: ["Bioprocessing", "CDMO Operations", "Biologics API", "Single-Use Systems"],
    image: "https://images.unsplash.com/photo-1579154204601-01588f351e67?auto=format&fit=crop&w=1200&q=80",
    body: [
      "As global pharmaceutical innovators seek to diversify biomanufacturing supply chains away from single-geography concentrations, leading Indian Contract Development and Manufacturing Organizations (CDMOs) are investing heavily in commercial continuous bioprocessing facilities.",
      "Perfusion bioreactors and integrated automated downstream purification trains are significantly reducing cleanroom footprint requirements by up to 65% while enhancing batch-to-batch consistency for complex monoclonal antibodies (mAbs), fusion proteins, and biosimilars.",
      "Regulatory bodies including the USFDA, EMA, and CDSCO are actively harmonizing continuous manufacturing validation standards. Real-time Process Analytical Technology (PAT) and automated sampling systems now allow continuous quality verification, cutting release turnaround times from weeks to days."
    ],
    isLocked: false,
    references: [
      {
        title: "International Council for Harmonisation: ICH Q13 Guideline on Continuous Manufacturing of Drug Substances and Drug Products",
        source: "ICH Harmonised Guideline",
        year: "2023-2026",
        doiOrUrl: "https://www.ich.org/page/quality-guidelines#13",
        type: "Regulatory Gazette",
      },
      {
        title: "Economic and operational comparison of fed-batch vs continuous bioprocessing for mAb production",
        source: "Nature Biotechnology, Vol. 41(4), pp. 512-524",
        year: "2024",
        doiOrUrl: "doi:10.1038/s41587-024-02109-x",
        type: "Journal",
      },
      {
        title: "APAC Biopharma CDMO Market Outlook & Capacity Benchmarking 2026-2032",
        source: "McKinsey Life Sciences Insights & Frost & Sullivan",
        year: "2026",
        doiOrUrl: "Report Ref: MED-APAC-2026",
        type: "Industry Report",
      },
    ],
  },
  {
    slug: "glp1-biosimilar-warchests-peptide-manufacturing",
    title: "The GLP-1 Biosimilar Warchests: India's Peptide Manufacturers Prepare for Patent Expirations",
    dek: "Solid-phase peptide synthesis innovations, recombinant yeast expression platforms, and high-volume sterile auto-injector assembly pipelines.",
    category: "Pharma",
    format: "Analysis",
    issueId: "issue-2026-09",
    authorId: "auth-rajiv-deshmukh",
    date: "Sep 01, 2026",
    readingTime: "7 min read",
    tags: ["Peptide Synthesis", "GLP-1 Biosimilars", "Sterile Injectables", "Auto-Injectors"],
    image: "https://images.unsplash.com/photo-1584308666744-24d5c474f2ae?auto=format&fit=crop&w=1200&q=80",
    body: [
      "With seminal semaglutide and tirzepatide patents approaching key regional expiry cliffs, top-tier Indian pharmaceutical manufacturers are executing multi-million dollar capital expenditure programs in large-scale peptide synthesis.",
      "The primary technological contest lies between automated Solid-Phase Peptide Synthesis (SPPS) and hybrid recombinant fermentation systems. Manufacturers capable of balancing high coupling efficiency with green solvent recovery protocols are poised to capture dominant global generic market share.",
      "Beyond active pharmaceutical ingredients (APIs), the true competitive moat is secure access to sterile pen-injector and auto-injector delivery hardware, driving strategic joint ventures with precision medical molding leaders."
    ],
    isLocked: true,
    references: [
      {
        title: "Synthetic Peptide Therapeutics: Regulatory Expectations for Impurity Profiling & Generic Substitution",
        source: "US FDA Center for Drug Evaluation and Research (CDER) Guidance",
        year: "2025",
        doiOrUrl: "FDA-2021-D-0398",
        type: "Regulatory Gazette",
      },
      {
        title: "Green chemistry advancements in solid-phase peptide synthesis of GLP-1 receptor agonists",
        source: "Journal of Medicinal Chemistry, Vol. 67(11), pp. 8890-8905",
        year: "2025",
        doiOrUrl: "doi:10.1021/acs.jmedchem.5c00321",
        type: "Journal",
      },
    ],
  },
  {
    slug: "ai-generative-protein-design-regulatory",
    title: "Generative AI in De Novo Protein Engineering: Regulatory Validation Benchmarks",
    dek: "Evaluating computational protein folding models, wet-lab validation loops, and IND filing standards for AI-designed therapies.",
    category: "AI-Health",
    format: "Analysis",
    issueId: "issue-2026-09",
    authorId: "auth-ananya-sen",
    date: "Aug 28, 2026",
    readingTime: "6 min read",
    tags: ["Generative AI", "Protein Engineering", "Regulatory Affairs", "Computational Biology"],
    image: "https://images.unsplash.com/photo-1532187863486-abf9dbad1b69?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Generative deep learning architectures—combining diffusion models with transformer-based sequence generators—have dramatically compressed the candidate discovery timeline for therapeutic proteins and nanobodies from years to mere weeks.",
      "However, transitioning computationally designed macromolecules from in silico predictions to clinical-grade candidates requires rigorous experimental benchmarking. Stability profiles, non-specific binding assays, and cryogenic electron microscopy (cryo-EM) structural conformations remain essential verification pillars.",
      "Regulatory reviewers across major agencies now demand detailed audit trails of model training sets, uncertainty quantification parameters, and immunogenicity risk scoring prior to clearing Investigational New Drug (IND) applications."
    ],
    isLocked: true,
    references: [
      {
        title: "De novo design of protein structure and function with RFdiffusion and ProteinMPNN",
        source: "Nature, Vol. 620, pp. 1089-1100",
        year: "2023",
        doiOrUrl: "doi:10.1038/s41586-023-06415-8",
        type: "Journal",
      },
      {
        title: "CDSCO Discussion Paper on AI/ML-Assisted Preclinical Discovery Pipelines",
        source: "CDSCO Directorate General of Health Services",
        year: "2026",
        doiOrUrl: "Doc No. CDSCO/DGHS/AI-2026",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "cdsco-ai-diagnostics-framework-2026",
    title: "CDSCO's 2026 AI Diagnostics Framework: What Regulatory Leads Need to Know",
    dek: "A detailed breakdown of new validation mandates, software-as-a-medical-device (SaMD) requirements, and clinical trial audit expectations.",
    category: "AI-Health",
    format: "Feature",
    issueId: "issue-2026-08",
    authorId: "auth-priya-nair",
    date: "Aug 15, 2026",
    readingTime: "7 min read",
    tags: ["Regulatory Affairs", "AI Diagnostics", "SaMD Compliance", "Clinical Operations"],
    image: "https://images.unsplash.com/photo-1576086213369-97a306d36557?auto=format&fit=crop&w=1200&q=80",
    body: [
      "The Central Drugs Standard Control Organisation (CDSCO) has introduced revised guidelines for AI-assisted diagnostic tools, bringing software-as-a-medical-device (SaMD) oversight into closer alignment with global IMDRF and USFDA frameworks.",
      "For regulatory affairs leads operating in India and the APAC corridor, this shift necessitates establishing formal Good Machine Learning Practice (GMLP) protocols, multi-center retrospective validation datasets, and post-market algorithmic drift monitoring.",
      "Special emphasis is placed on clinical diversity across regional demographic cohorts, preventing bias in automated radiology triage, ophthalmic screening, and computational pathology models."
    ],
    isLocked: false,
    references: [
      {
        title: "Medical Devices Rules (2017 & 2026 Amendments) for SaMD and AI Clinical Decision Support",
        source: "Gazette of India, Ministry of Health & Family Welfare",
        year: "2026",
        doiOrUrl: "G.S.R. 204(E)",
        type: "Regulatory Gazette",
      },
      {
        title: "International Medical Device Regulators Forum (IMDRF): Machine Learning-enabled Medical Devices",
        source: "IMDRF Technical Document N67",
        year: "2024",
        doiOrUrl: "imdrf.org/documents/n67",
        type: "Industry Report",
      },
      {
        title: "Clinical validation standards for multi-ethnic radiology triage algorithms in South Asia",
        source: "The Lancet Digital Health, Vol. 8(3), e180-e192",
        year: "2026",
        doiOrUrl: "doi:10.1016/S2589-7500(25)00341-9",
        type: "Journal",
      },
    ],
  },
  {
    slug: "surgical-robotics-ip-licensing-apac",
    title: "Navigating IP & Licensing Partnerships for Next-Gen Surgical Platforms",
    dek: "How MedTech innovators are structuring co-development agreements across emerging APAC manufacturing hubs.",
    category: "MedTech",
    format: "Analysis",
    issueId: "issue-2026-08",
    authorId: "auth-marcus-ob",
    date: "Aug 10, 2026",
    readingTime: "5 min read",
    tags: ["Surgical Robotics", "IP Licensing", "MedTech M&A", "Commercial Strategy"],
    image: "https://images.unsplash.com/photo-1581091226825-a6a2a5aee158?auto=format&fit=crop&w=1200&q=80",
    body: [
      "The rapid clinical adoption of robotic-assisted laparoscopic and orthopedic surgery across South and Southeast Asian tertiary hospitals has catalyzed unprecedented cross-border licensing transactions.",
      "Early-stage device innovators with novel haptic feedback actuators or modular robotic arms are partnering with regional contract manufacturers to achieve cost-efficient localized production without compromising sub-millimeter precision tolerances.",
      "Structuring cross-border joint ventures requires meticulous freedom-to-operate (FTO) patent analyses, clear field-of-use allocations, and reciprocal clinical data sharing agreements."
    ],
    isLocked: false,
    references: [
      {
        title: "Global Robotic Surgery Patent Landscape & APAC Freedom-to-Operate Analysis",
        source: "WIPO Patent Analytics Report & MedTech Strategy Group",
        year: "2025",
        doiOrUrl: "WIPO/PUB/2025/MEDTECH",
        type: "Industry Report",
      },
      {
        title: "Economic evaluation of robotic vs laparoscopic radical prostatectomy in tertiary hospital networks",
        source: "British Journal of Surgery, Vol. 112(6), pp. 780-791",
        year: "2025",
        doiOrUrl: "doi:10.1093/bjs/znab302",
        type: "Journal",
      },
    ],
  },
  {
    slug: "point-of-care-microfluidics-silicon-biochips",
    title: "Point-of-Care Microfluidics: Scaling Silicon-Biochip Fabrication in Indian EMS Hubs",
    dek: "From PDMS prototypes to injection-molded cyclic olefin polymers for decentralized multiplex immunoassays.",
    category: "MedTech",
    format: "Feature",
    issueId: "issue-2026-08",
    authorId: "auth-leila-ahmadi",
    date: "Aug 08, 2026",
    readingTime: "6 min read",
    tags: ["Microfluidics", "Biochips", "Point-of-Care Diagnostics", "MEMS"],
    image: "https://images.unsplash.com/photo-1579154204601-01588f351e67?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Translating laboratory-bench microfluidic assays into robust point-of-care commercial cartridges is one of MedTech's steepest engineering hurdles.",
      "Indian electronics manufacturing service (EMS) providers are expanding into cleanroom biochip packaging, transitioning from polydimethylsiloxane (PDMS) prototypes to high-throughput injection-molded Cyclic Olefin Copolymers (COC).",
      "Integrated micro-pumps, lyophilized reagent beads, and electrochemical biosensing arrays now enable quantitative troponin, multiplex infectious disease, and antimicrobial susceptibility testing within 15 minutes at rural healthcare clinics."
    ],
    isLocked: false,
    references: [
      {
        title: "Manufacturing readiness levels for microfluidic point-of-care diagnostic devices",
        source: "Lab on a Chip, Vol. 25(2), pp. 245-261",
        year: "2025",
        doiOrUrl: "doi:10.1039/D4LC00912A",
        type: "Journal",
      },
      {
        title: "In-Vitro Diagnostics (IVD) Performance Evaluation Standards under CDSCO CLIA Equivalent Protocols",
        source: "Indian Council of Medical Research (ICMR) Validation Guidelines",
        year: "2026",
        doiOrUrl: "ICMR/IVD-STD-2026",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "federated-learning-radiology-privacy-models",
    title: "Federated Learning for Multi-Hospital Radiology: Zero-Data Egress AI Models",
    dek: "Training deep diagnostic networks across hospital consortia while maintaining strict DPDP compliance and patient anonymity.",
    category: "AI-Health",
    format: "Digest",
    issueId: "issue-2026-07",
    authorId: "auth-siddharth-rao",
    date: "Jul 22, 2026",
    readingTime: "5 min read",
    tags: ["Federated Learning", "Medical Imaging", "DPDP Act", "Data Privacy"],
    image: "https://images.unsplash.com/photo-1516549655169-df83a0774514?auto=format&fit=crop&w=1200&q=80",
    body: [
      "With the enforcement of national data protection statutes across APAC, traditional centralized data lake models for medical AI training have become legally complex and commercially vulnerable.",
      "Federated learning architectures allow AI algorithms to train locally on on-premise hospital PACS servers, aggregating model weight gradients via secure homomorphic encryption without transferring raw DICOM patient scans outside hospital perimeters.",
      "Recent consortia across oncology and neuro-imaging hospitals demonstrate that federated models achieve over 98% AUC parity compared to centrally trained models while completely satisfying regulatory data sovereignty requirements."
    ],
    isLocked: false,
    references: [
      {
        title: "Digital Personal Data Protection (DPDP) Rules & Healthcare Data Governance in India",
        source: "Ministry of Electronics and Information Technology (MeitY)",
        year: "2024-2026",
        doiOrUrl: "meity.gov.in/dpdp-rules-2024",
        type: "Regulatory Gazette",
      },
      {
        title: "Federated learning enables big data for rare disease clinical trials without sharing patient data",
        source: "Nature Medicine, Vol. 28, pp. 2229-2238",
        year: "2022",
        doiOrUrl: "doi:10.1038/s41591-022-02155-3",
        type: "Journal",
      },
    ],
  },
  {
    slug: "mrna-cold-chain-logistics-tier2",
    title: "mRNA Therapeutics & Cold-Chain Realities in Tier-2 Distribution",
    dek: "Operational strategies for maintaining ultracold storage integrity across decentralized health networks.",
    category: "Pharma",
    format: "Interview",
    issueId: "issue-2026-07",
    authorId: "auth-arun-sharma",
    date: "Jul 18, 2026",
    readingTime: "6 min read",
    tags: ["mRNA Platforms", "Cold-Chain Logistics", "Vaccine Distribution", "IoT Telemetry"],
    image: "https://images.unsplash.com/photo-1584308666744-24d5c474f2ae?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Lipid nanoparticle (LNP)-formulated mRNA therapeutics offer revolutionary potential for cancer vaccines and infectious diseases, yet their physical stability demands ultra-low temperature management throughout distribution.",
      "Dr. Arun Sharma discusses real-time temperature telemetry integrations, vacuum insulated panel (VIP) containers, and phase-change material (PCM) coolants deployed across semi-urban distribution routes.",
      "Simultaneously, formulation chemistry advances targeting lyophilized and room-temperature-stable LNP configurations are beginning to demonstrate promising preclinical pharmacokinetic profiles."
    ],
    isLocked: false,
    references: [
      {
        title: "Lipid Nanoparticle Formulations for mRNA Delivery: Physical Stability & Degradation Pathways",
        source: "Advanced Drug Delivery Reviews, Vol. 198, 114890",
        year: "2023",
        doiOrUrl: "doi:10.1016/j.addr.2023.114890",
        type: "Journal",
      },
      {
        title: "WHO Technical Report Series No. 961: Annex 9 Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products",
        source: "World Health Organization",
        year: "2024",
        doiOrUrl: "who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_961",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "cart-cell-therapy-manufacturing-apac",
    title: "Decentralized CAR-T Cell Therapy: Overcoming Manufacturing Bottlenecks in APAC",
    dek: "Point-of-care viral vector transduction, automated cell-processing isolators, and cost-reduction pathways.",
    category: "Pharma",
    format: "Feature",
    issueId: "issue-2026-07",
    authorId: "auth-vikram-malhotra",
    date: "Jul 12, 2026",
    readingTime: "8 min read",
    tags: ["Cell & Gene Therapy", "CAR-T Protocols", "Oncology", "Biomanufacturing"],
    image: "https://images.unsplash.com/photo-1532187863486-abf9dbad1b69?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Autologous CAR-T cell therapies have transformed hematologic oncology outcomes, yet global access remains severely restricted by centralized manufacturing turnaround times of 3 to 4 weeks and staggering therapy costs.",
      "Dr. Vikram Malhotra explores the clinical implementation of closed-system, automated benchtop cell processors installed directly inside hospital GMP suites, reducing vein-to-vein timelines to under 10 days.",
      "Early clinical trials in India demonstrate that localized CAR-T production can lower treatment costs by upwards of 70% while maintaining equivalent expansion and persistence kinetics in refractory leukemia patients."
    ],
    isLocked: true,
    references: [
      {
        title: "NexCAR19 Clinical Efficacy & Safety in Relapsed/Refractory B-cell Malignancies",
        source: "Lancet Oncology, Vol. 25(8), pp. 1002-1015",
        year: "2024",
        doiOrUrl: "doi:10.1016/S1470-2045(24)00298-X",
        type: "Clinical Trial",
      },
      {
        title: "Automated point-of-care manufacturing of gene-modified cell therapies",
        source: "Nature Reviews Bioengineering, Vol. 2, pp. 410-426",
        year: "2024",
        doiOrUrl: "doi:10.1038/s44222-024-00185-1",
        type: "Journal",
      },
    ],
  },
  {
    slug: "wearable-continuous-biosensing-payer-reimbursement",
    title: "Wearable Continuous Biosensors: Payer Reimbursement & Clinical Validity",
    dek: "How continuous glucose and multi-analyte biosensors are shifting from consumer wellness gadgets into clinical disease management.",
    category: "MedTech",
    format: "Analysis",
    issueId: "issue-2026-06",
    authorId: "auth-leila-ahmadi",
    date: "Jun 24, 2026",
    readingTime: "6 min read",
    tags: ["Biosensors", "Wearables", "Payer Reimbursement", "HEOR Evidence"],
    image: "https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Continuous glucose monitors (CGMs) and microneedle interstitial fluid sensing arrays are rapidly expanding beyond diabetic care into metabolic syndrome, cardiology, and sports medicine management.",
      "The pivotal transition from out-of-pocket consumer purchases to widespread institutional insurance coverage hinges on rigorous Health Economics and Outcomes Research (HEOR) data proving reduction in acute hospitalization rates.",
      "Regulatory pathways are clarifying around combined digital therapeutic (DTx) software that pair continuous analyte telemetry with AI-guided insulin titrations and nutritional nudges."
    ],
    isLocked: false,
    references: [
      {
        title: "Health economic evaluation of continuous glucose monitoring in high-risk type 2 diabetes",
        source: "Diabetes Care, Vol. 48(4), pp. 601-611",
        year: "2025",
        doiOrUrl: "doi:10.2337/dc24-1809",
        type: "Journal",
      },
      {
        title: "IRDAI Draft Master Circular on Digital Health Devices & Home Health Monitoring Coverage",
        source: "Insurance Regulatory and Development Authority of India",
        year: "2025",
        doiOrUrl: "IRDAI/HLT/CIR/2025/112",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "autonomous-clinical-trial-protocol-llms",
    title: "Autonomous Clinical Trial Protocol Drafting via Domain-Specific LLMs",
    dek: "Accelerating inclusion/exclusion criteria formulation and statistical analysis plans while avoiding hallucinations.",
    category: "AI-Health",
    format: "Digest",
    issueId: "issue-2026-06",
    authorId: "auth-siddharth-rao",
    date: "Jun 14, 2026",
    readingTime: "5 min read",
    tags: ["Clinical Trials", "LLMs", "Protocol Design", "NLP AI Pipelines"],
    image: "https://images.unsplash.com/photo-1507003211169-0a1dd7228f2d?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Clinical protocol drafting has historically represented one of the most labor-intensive phases of drug development, requiring cross-disciplinary inputs across biostatistics, toxicology, and regulatory teams.",
      "Fine-tuned clinical domain models trained on thousands of historical ClinicalTrials.gov filings and FDA briefing documents are now automating the synthesis of primary and secondary endpoints, dosing regimens, and adverse event grading tables.",
      "With human-in-the-loop validation frameworks, biopharma sponsors report up to a 60% reduction in protocol amendment frequency during active trial execution."
    ],
    isLocked: false,
    references: [
      {
        title: "Benchmarking large language models on clinical trial protocol optimization and amendment risk reduction",
        source: "NEJM AI, Vol. 1(5), AIoa2300189",
        year: "2024",
        doiOrUrl: "doi:10.1056/AIoa2300189",
        type: "Journal",
      },
      {
        title: "FDA Guidance for Industry: Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products",
        source: "US FDA Center for Drug Evaluation & Research",
        year: "2025",
        doiOrUrl: "FDA-2023-N-3624",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "adc-high-potency-containment-cdmo",
    title: "Antibody-Drug Conjugates (ADCs): High-Potency Containment & Linker Scaling",
    dek: "Navigating SafeBridge Category 4 containment, cytotoxic payload synthesis, and site-specific bioconjugation.",
    category: "Pharma",
    format: "Feature",
    issueId: "issue-2026-05",
    authorId: "auth-ananya-sen",
    date: "May 20, 2026",
    readingTime: "7 min read",
    tags: ["ADCs", "Bioconjugation", "High-Potency Containment", "Oncology"],
    image: "https://images.unsplash.com/photo-1579154204601-01588f351e67?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Antibody-Drug Conjugates (ADCs) have emerged as the fastest growing modality in targeted oncology, combining the exquisite selectivity of monoclonal antibodies with potent cytotoxic small-molecule warheads.",
      "Handling potent payloads with Occupational Exposure Limits (OEL) below 50 ng/m³ requires specialized SafeBridge Category 4 isolator suites, dedicated HVAC recirculation loops, and rigorous operator safety controls.",
      "Leading Asian CDMOs are investing in integrated bioconjugation suites that house antibody production, payload-linker synthesis, conjugation, and sterile lyophilization under a single unified quality system."
    ],
    isLocked: true,
    references: [
      {
        title: "Next-generation antibody-drug conjugates: Linker chemistry, payload diversity, and bystander killing mechanisms",
        source: "Nature Reviews Clinical Oncology, Vol. 21, pp. 201-224",
        year: "2024",
        doiOrUrl: "doi:10.1038/s41571-023-00850-2",
        type: "Journal",
      },
      {
        title: "SafeBridge Consultants Containment Verification Protocols for High Potency Active Pharmaceutical Ingredients (HPAPI)",
        source: "Occupational Toxicology & Industrial Hygiene Standard Guideline",
        year: "2025",
        doiOrUrl: "safebridge.com/guidelines/cat4",
        type: "Industry Report",
      },
    ],
  },
  {
    slug: "targeted-alpha-therapeutics-actinium-theranostics",
    title: "Targeted Alpha Therapies (TAT): Scaling Actinium-225 & Cyclotron Radiopharmacy Networks",
    dek: "How short-half-life radioisotope logistics and specialized radiopharmaceutical GMP cleanrooms are reshaping prostate cancer treatment.",
    category: "Pharma",
    format: "Feature",
    issueId: "issue-2026-03",
    authorId: "auth-christine-vance",
    date: "Mar 18, 2026",
    readingTime: "9 min read",
    tags: ["Radiopharmaceuticals", "Theranostics", "Actinium-225", "Nuclear Medicine"],
    image: "https://images.unsplash.com/photo-1516549655169-df83a0774514?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Targeted Alpha Therapies (TAT) utilizing high linear energy transfer (LET) radionuclides like Actinium-225 and Lead-212 represent a potent new frontier in precision radiation oncology.",
      "Because alpha particles travel only a few cell diameters, they deliver concentrated double-strand DNA breaks directly to PSMA-expressing tumor cells while sparing adjacent healthy bone marrow and salivary tissue.",
      "The primary operational bottleneck is half-life logistics. With Ac-225 exhibiting a 10-day half-life and Lu-177 a 6.6-day window, commercial success demands specialized regional radiopharmacies located within 3 hours of major nuclear airport nodes."
    ],
    isLocked: false,
    references: [
      {
        title: "Actinium-225-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer",
        source: "New England Journal of Medicine, Vol. 391(12), pp. 1105-1118",
        year: "2025",
        doiOrUrl: "doi:10.1056/NEJMoa2401890",
        type: "Clinical Trial",
      },
      {
        title: "IAEA Nuclear Medicine Resources Manual: Radiopharmaceutical GMP & Cyclotron Operations",
        source: "International Atomic Energy Agency (IAEA) Technical Series",
        year: "2025",
        doiOrUrl: "iaea.org/publications/14820",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "enzymatic-biocatalysis-green-api-synthesis",
    title: "Green Biocatalysis in API Synthesis: Replacing Organic Solvents with Engineered Enzymes",
    dek: "How protein directed evolution is enabling stereoselective enzymatic cascades for commercial-scale active pharmaceutical ingredients.",
    category: "Pharma",
    format: "Analysis",
    issueId: "issue-2026-02",
    authorId: "auth-alok-verma",
    date: "Feb 24, 2026",
    readingTime: "8 min read",
    tags: ["Synthetic Biology", "Biocatalysis", "Green Chemistry", "API Manufacturing"],
    image: "https://images.unsplash.com/photo-1532187863486-abf9dbad1b69?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Traditional small-molecule API synthesis frequently relies on multi-step chemical reactions requiring heavy metal catalysts, hazardous organic solvents, and extreme temperature conditions.",
      "Engineered enzymes—transaminases, ketoreductases, and monooxygenases evolved via machine learning directed evolution—are enabling single-pot biocatalytic transformations in mild aqueous buffers at room temperature.",
      "Biopharma companies implementing biocatalytic synthesis report up to an 80% reduction in Process Mass Intensity (PMI) alongside significant reductions in hazardous waste disposal costs."
    ],
    isLocked: false,
    references: [
      {
        title: "Machine learning-guided directed evolution of enzymes for industrial biocatalysis",
        source: "Science, Vol. 384(6695), pp. 542-550",
        year: "2024",
        doiOrUrl: "doi:10.1126/science.ade3042",
        type: "Journal",
      },
      {
        title: "ACS Green Chemistry Institute Pharmaceutical Round Table: Process Mass Intensity Benchmarks",
        source: "American Chemical Society Green Chemistry Institute",
        year: "2025",
        doiOrUrl: "acs.org/gci/pharma-benchmarks-2025",
        type: "Industry Report",
      },
    ],
  },
  {
    slug: "ai-pharmacovigilance-automated-signal-detection",
    title: "AI-Powered Pharmacovigilance: Automated Adverse Event Extraction & CDSCO Signal Audits",
    dek: "Deploying bio-LLMs and optical character recognition across multi-lingual post-market safety surveillance channels.",
    category: "AI-Health",
    format: "Digest",
    issueId: "issue-2026-03",
    authorId: "auth-siddharth-rao",
    date: "Mar 10, 2026",
    readingTime: "6 min read",
    tags: ["Pharmacovigilance", "AI Safety Signals", "NLP Pipelines", "Post-Market Surveillance"],
    image: "https://images.unsplash.com/photo-1507003211169-0a1dd7228f2d?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Post-market pharmacovigilance teams face exponential increases in adverse event (AE) reporting volume across spontaneous patient portals, EHRs, social channels, and clinical trial safety registries.",
      "Domain-adapted NLP pipelines utilizing specialized clinical transformers automate ICSR (Individual Case Safety Report) intake, MedDRA coding, and causality assessment scoring with over 96% accuracy.",
      "Automated disproportionality analytics—such as Information Component (IC) and Empirical Bayes Geometric Mean (EBGM)—allow safety leads to detect emerging risk signals months earlier than manual periodic safety update reports (PSURs)."
    ],
    isLocked: false,
    references: [
      {
        title: "Automated adverse event extraction from electronic health records using clinical language models",
        source: "Drug Safety, Vol. 48(2), pp. 145-159",
        year: "2025",
        doiOrUrl: "doi:10.1007/s40264-024-01490-w",
        type: "Journal",
      },
      {
        title: "Pharmacovigilance Programme of India (PvPI): Guidance on Computerized Safety Signal Detection",
        source: "Indian Pharmacopoeia Commission (IPC)",
        year: "2026",
        doiOrUrl: "ipc.gov.in/pvpi-ai-guidance-2026",
        type: "Regulatory Gazette",
      },
    ],
  },
  {
    slug: "decentralized-clinical-trials-direct-to-patient-ip",
    title: "Decentralized Clinical Trials (DCT): Solving Direct-to-Patient Investigational Product Logistics",
    dek: "Home nursing networks, digital eConsent, and temperature-verified drug delivery across semi-urban patient cohorts.",
    category: "Pharma",
    format: "Analysis",
    issueId: "issue-2026-02",
    authorId: "auth-priya-nair",
    date: "Feb 14, 2026",
    readingTime: "7 min read",
    tags: ["Clinical Operations", "Decentralized Trials", "Direct-to-Patient", "eConsent"],
    image: "https://images.unsplash.com/photo-1584308666744-24d5c474f2ae?auto=format&fit=crop&w=1200&q=80",
    body: [
      "Decentralized and hybrid clinical trial models have transitioned from crisis-era emergency measures into permanent strategic advantages for biopharma sponsors seeking higher patient retention and demographic diversity.",
      "The pivotal operational challenge is direct-to-patient (DTP) Investigational Medicinal Product (IMP) distribution. Ensuring temperature-controlled unblinded delivery directly to patient doorsteps requires tamper-evident smart packaging and verified chain-of-custody handoffs.",
      "Regulatory bodies including CDSCO and USFDA now provide explicit guidance on remote eConsent verification, local phlebotomy network auditing, and continuous real-time adverse event ePRO reporting."
    ],
    isLocked: false,
    references: [
      {
        title: "FDA Guidance for Industry: Decentralized Clinical Trials for Drugs, Biological Products, and Devices",
        source: "US FDA Center for Drug Evaluation & Research",
        year: "2024",
        doiOrUrl: "FDA-2022-D-2870",
        type: "Regulatory Gazette",
      },
      {
        title: "Patient recruitment and retention metrics in hybrid vs traditional phase-III oncology trials",
        source: "Contemporary Clinical Trials, Vol. 138, 107450",
        year: "2024",
        doiOrUrl: "doi:10.1016/j.cct.2024.107450",
        type: "Journal",
      },
    ],
  },
]
